Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz

Int J Antimicrob Agents. 2002 Sep;20(3):223-6. doi: 10.1016/s0924-8579(02)00164-4.

Abstract

The study evaluated the development of drug resistance in a group of HIV-1 patients. After failure to respond to previous therapy with two non-nucleoside reverse transcriptase inhibitors (NNRTIs), as assessed by the presence of a rebound in viral load or a constant high level of HIV plasma viraemia, the patients were treated with a combination of stavudine, lamivudine and efavirenz (EFV). Results showed that viruses carrying primary mutations, usually K103N, T215Y and M41L, presented higher levels of HIV-1 RNA, suggesting an association between a precise mutation pattern and treatment failure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkynes
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • Benzoxazines
  • Cyclopropanes
  • Drug Resistance, Viral*
  • Genes, Viral / genetics
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • Humans
  • Lamivudine / pharmacology*
  • Lamivudine / therapeutic use
  • Mutation / genetics
  • Oxazines / pharmacology*
  • Oxazines / therapeutic use
  • RNA, Viral / analysis
  • Stavudine / pharmacology*
  • Stavudine / therapeutic use
  • Viral Load
  • Viremia / virology

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • Oxazines
  • RNA, Viral
  • Lamivudine
  • Stavudine
  • efavirenz